Cyclotron is a device that uses the magnetic field and electric field to jointly make charged particles perform cyclotron motions, and repeatedly accelerated by a high-frequency electric field during motion.
The EchoMRI™-100 body composition analyzer can provide accurate measurements of fat, lean meat, free water and total water for living mice weighing less than 100g.
CellRad is a compact biological X-ray irradiator, which generates 10-130KV high-energy X-rays using artificial electronic devices to irradiate cells.
The MUCHA is a γ-radiation measurement system, designed for the radio spectroscopy analysis of radio pharmaceutical samples.
In actual production, 18F ions account for most of the proportion, and the corresponding production technology has been improved the fastest.
The EchoMRI™-3-in-1body composition analyzer has three vertical holes, which are used for living mice under 100g,
As the economic choice of high- throughput irradiation, with compact small box design for surface irradiation research, it is an ideal scheme to provide high-dose irradiation for cells and tissue culture.
The PC-based Dose Calibrator is designed for the fast and accurate determination of the activity or volume activity of radiopharmaceuticals that are used in the nuclear medicine for diagnostics and therapy.
The newest freezing point Osmometer allows an easy and fast determination of the osmolality of various aqueous solutions.
The Safira is an in-line filter integrity tester, available as stand-alone unit or as an extension of a raytest SynChrom-system.
Tc -99m is the most widely used radiometal in medical diagnostic and therapeutic applications.
The EchoMRI™-4-in-1 body composition analyzer has four vertical holes, which are respectively used for living rats or animals under 500g/ 700g/900g/1100g, living mice under 100g, organ or isolated tissue samples under 7g, and biopsy tissue samples under 0
Marita Star is a high-efficiency and high-sensitivity β -nuclide thin-layer chromatograph (TLC detector).
The miniGITA Dual is a versatile state-of-the-art radio TLC system. A complete range of detector probes allow the measurement of nearly every isotope.
Ultra sensitive TLC analyzer for nuclides such as 3H, 14C, 32P, 90Y ...
Adopting large box design, it can accommodate a wide range of accessories, able to be upgraded to OptiMAX multi-modality imaging system (including X-ray imaging, bioluminescence and fluorescence)
The miniGITA Single is the new version of the well know miniGITA Star. It is a versatile state-of-the-art radio TLC system.
The Ga-68 generator is a closed system that includes a titanium dioxide decay bed containing Ge-68 and is eluted with 0.1M hydrochloric acid to produce Ga-68
The EchoMRI™-Human body composition analyzer is divided into three models, which can provide accurate measurement of fat, lean meat, free water and total water for newborns under 12kg, teenagers under 80kg and adults under 250kg, respectively.
MIRA* is a highly sensitive μ-HPLC radioactivity flow detector.
The Gabi Nova is a versatile state-of-the-art radio flow monitor. A large range of detector probes allow the measurement of nearly every isotope, ensuring the Gabi Nova is ideally suited for radio flow measurements in nuclear medicine, SPECT or PET labora
Liquid scintillation is the most sensitive detection method for low energy beta nuclides such as 3H.
Compact, completely shielded, independent x-ray irradiator, without use site and personnel restrictions.
The radio-HPLC has been designed to get very short analysis time, very high sensitivity without compromising the resolution.
Rhenium -188 (with a predominant β maximum energy of 2.12MeV and a predominant γ energy of 155keV and a half-life of 16.98h) is one of the excellent therapeutic nuclides,
LCT-200 is a Micro-CT system for multi-functional scanning of mice, rats and rabbits, performing scanning on the whole body (including bone, fat, blood vessels, whole body organs, etc.) of experimental animals.
Self-shielding irradiators are suitable for small animals and cells in a compact laboratory environment.
18F-FDG automatic synthesis device, which can automatically complete the online synthesis and purification of 18F- radiopharmaceutical;
Adopting self-shielding large box body design, it can accommodate a wide range of accessories, able to be upgraded to OptiMAX multi-modality imaging system (including X-ray imaging, bioluminescence and fluorescence)
Gaia V2 is a new versatile radiopharmaceutical synthesizer for rapid labeling of radionuclides (68Ga、90Y、177Lu......) and active peptides.
Fully shielded, independent X-ray irradiator, without use site and personnel restrictions. The high-power research platform for cell and tissue culture is an ideal platform for directional irradiation of small animals.
LUNA is a synthesis unit for the labeling of peptides Iike DOTAToc with radioactive metals (e.g. 177Lu) delivered in a capped vessel.
Optical guided precision biological X-ray irradiator can mark tumor cells by bioluminescence, mark tumor drugs by fluorescent dyes, and locate tumor drugs by X-ray.
Self-shielding large box body design, the ability to accommodate a wide range of accessories, OptiMAX multi-modal imaging system (including X-ray imaging, bioluminescence and fluorescence)
Stainless steel single-layer synthetic hot cell. Meet the use requirements of volume synthesis module and ancillary equipment.
The nanoScan® PET system is equipped with the finest detector crystal needles ensuring high spatial resolution down to 700 μm in vivo.
NanoScan® SPECT system combines high-end detector technology, porous collimator technology with TeraTomo 3D reconstruction algorithm
MultiScanTM LFER 150 system is a reliable research tool for primate PET/CT scanning with high resolution at present. It is widely used from routine laboratory experiments to preclinical scientific research.
Magnetic resonance imaging (MRI) products can visually show the specific distribution of adipose tissue. By selecting different experimental angles, we can analyze the distribution area of adipose tissue at different locations
The design of the MultiRad350 allows high dose and uniform depth of irradiation, making it ideal for very dense biological specimen applications.
QC-Cubicle radiopharmaceutical quality control integrated solution covers an area of only 1.2m2, effectively saving laboratory space, and meets the QC standard of European Pharmacopoeia.
X-RAD SmART System 3D image-guided precision irradiation system, which combines the 3D volume imaging of CT with highly accurate specimen positioning, can accurately locate specific targets in mice
Transfusion associated graft versus host disease (TA-GVHD) is one of the most serious complications of blood transfusion.
Transfusion associated graft versus host disease (TA-GVHD) is one of the most serious complications of blood transfusion.
The natural radioisotope cesium-137 was used as the source for ionizing ray generation, which occurs from radioactive nuclei at α Decay β New nuclei generated after decay tend to be at high energy level,
The Endosafe® nexgen-PTS™ is a rapid, point-of-use test system that provides quantitative LAL results within 15 minutes. The nexgen-PTS™ utilizes LAL reagents in an FDA-licensed disposable test cartridge with a handheld reader for a completely contained
CR 35 Bio is a high-speed isotope scanner suitable for all types of imaging plates/storage screens below 35x43cm.
The new nanoScan® systems follow the footsteps of the first ever commercially available integrated preclinical PET/MRI system introduced by Mediso in 2011.
The nanoScan® MRI systems are equipped with a state-of-the-art cryogen-free superconducting magnet.
The nanoScan® SPECT system images radiotracers with absolute quantification, high sensitivity and high spatial resolution down to 0.3 mm in vivo.
Approval of SHINE Europe grant proposal by Dutch government first step toward terbium production
The members of the Brugarolas lab have recently published their research on the biodistribution and dosimetry for a demyelination tracer in the European Journal of Nuclear Medicine and Molecular Imaging.
Data from the phase 1 LuMIERE study highlighted that targeted radiotherapy agent 177Lu-FAP-2286 demonstrated a manageable safety profile and promising preliminary antitumor activity.
ORNL has spent the past decade designing, researching, developing and prototyping the two types of isotope separation equipment that SIPRC will employ.
PET imaging with prostate-specific antigen (PSMA) radiotracers can help surgeons spare nerves in patients undergoing radical prostatectomy, according to a study published November 1 in Urologic Oncology.
Brain PET imaging has revealed that mania in patients with bipolar disorder may be associated with lower density levels of dopamine transporter (DAT), according to a study published November 2 in JAMA Psychiatry.
A shortage in global supplies of molybdenum-99 (Mo-99) and iodine-131 (I-131) is expected due to a mechanical failure at Belgium's BR2 reactor in Mol, according to a report by Nuclear Medicine Europe (NMEU).
Positron emission tomography (PET) is a powerful tool for the visualization of metabolism, especially the measurement of glucose uptake in vivo.
The phase 3 ZIRCON trial (NCT03849118) exploring the novel PET imaging radiopharmaceutical TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) has met its co-primary endpoints.1
NorthStar Medical Radioisotopes, located in Beloit, Wisconsin, recognizes the urgent medical need for technetium-99m (Tc-99m) to ensure patients have access to critical diagnostic imaging tests.
In response to the shortage of molybdenum-99 (Mo-99) that the nuclear medicine community faces in November 2022, the world’s major processing facilities and reactors confirm the details of their plans to continue serve the 40 million patients a year who u
Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced that its investigational therapeutic radiopharmaceutical
As the saying goes, when all you have is a hammer, everything looks like a nail; and some medicines can work that way, spreading throughout the body and "treating" every cell, without discrimination.
Nearly 70 percent of breast cancer patients could find out if their cancer has spread to their lymph nodes without having to undergo an invasive sentinel node biopsy.
Hybrid PET/MRI shows promise in diagnosing and evaluating infection and inflammation, but most of the evidence came from anecdotal reports or small cohorts.,
Collaboration pairs POINT’s expertise in next generation radioligand development and manufacturing with Lantheus’ commercial leadership in PSMA PET and radiopharmaceuticals
Beta and alpha radionuclide therapies (RNTs) are novel and effective treatment options for metastatic castration-resistant prostate cancer (mCRPC), as the survival benefit of chemotherapy and drugs that target androgen signaling is limited.
Complements NorthStar’s growing radioisotope production programs, providing powerhouse combination of capabilities and expertise to advance patient care
A new French study has underlined the high accuracy of F-18 fluorodopa (FDOPA)-PET to differentiate recurrent malignant gliomas from treatment-related changes and emphasized the importance of the dynamic slope as a potential diagnostic and prognostic biom
Fibroblast activation protein inhibitor (FAPI)-PET diagnostic cancer imaging may be performed reliably as early as 10 minutes after radiotracer injection -- a significant reduction of the typical one-hour wait period for tracers such as FDG-PET, European
A new molecular imaging radiotracer can precisely diagnose a variety of cancers, providing a roadmap to identify patients who may benefit from targeted radionuclide therapies.
To meet high demand, Telix Pharmaceuticals Limited announces Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) with up to 50mCi for radiolabeling is available for use on 100mCi (millicurie) gallium generators, an important developme
A new report in Cureus once again highlights the far-reaching effects of COVID, detailing the discovery of incidental pancreatitis triggered by the respiratory virus in a patient who was otherwise asymptomatic [1].
Medical technology company Radiopharm Theranostics says new data released by Imperial College London adds weight to the company’s belief its F-18 Pivalate tracer can be used to monitor brain cancer.
ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPETTM) imaging agent and radiopharmaceutical therapy (RPT) products, is pleased to announce the signing of a new non-exclusive License and Supply Agreement with
Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has announced the approval of its Investigational New Drug (IND) application by the US FDA to evaluate its SAR-Bombesin product
Curium, the world’s leading nuclear medicine company, announced today that it intends to submit updated labeling to the U.S. Food and Drug Administration (FDA) for its generic version of DaTscan™ (Ioflupane I 123 Injection) to include a new indication and
Cancer patients across Scotland are having crucial scans cancelled due to a global shortage of an isotope used in medical imaging.
NorthStar Medical Radioisotopes has completed construction and all equipment installation at its new facility in Beloit, Wisconsin, to produce the medical radioisotope molybdenum-99 without the use of highly enriched uranium.
Full-Life Technologies, a fully integrated global radiotherapeutics company, today announced an agreement to acquire New Jersey-based Focus-X Therapeutics
Nearly 30% of patients with low-risk prostate cancer were excluded from focal ablative therapy after undergoing PET/MRI imaging with F-18 DCFPyL, or Pylarify, which could lead to reduced treatment failure, according to a study presented at RSNA 2022 meeti
A study presented at the RSNA conference found gallium-68 PSMA imaging identified more lesions in patients with prostate cancer, compared with other methods, and changed case management in 76.5% of those with biochemically recurrent disease and 45.5% of t
First results from LIGHTHOUSE trial presented at 23rd Annual Scientific Meeting in Urologic Oncology (SUO)
POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today released new preclinical data from the Company’s pan-cancer fibroblast
Triplet therapy incorporating an alpha prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT, 225Ac-J591)
Oak Ridge National Lab team investigate factors underpinnning Ra2+ complex stability and selectivity in attempt to expand the therapeutic utility of radium-223
Researchers found using PET to map coronary blood flow and outcomes such as subendocardial ischemia in patients with heart disease may be better than an angiogram in determining the need for coronary stents or bypass surgery, according to a study in JACC:
Without accurate diagnostics, it is difficult to talk about effective treatment of patients, especially in the case of cancer. Today, as much as 80% of diagnostic procedures using radiopharmaceuticals require the use of molybdenum-99.
Today, Novartis announced the pivotal Phase III PSMAfore study with PluvictoTM (INN: lutetium (177Lu) vipivotide tetraxetan), a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, met its primary endpoint.
Framatome signed two contracts with NRG to supply enriched uranium targets and fuel elements for the High Flux Reactor (HFR) in the Netherlands.
The phase 1 PROPELLER trial exploring the novel PSMA-PET imaging product 64Cu-SAR-bisPSMA in patients with treatment-naïve, histologically confirmed prostate cancer who are scheduled for radical prostatectomy has met its primary end points.1
ImaginAb Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent and radiopharmaceutical therapy (RPT) products
A special report just published in Radiology offers a rare overview of the number of radiology exams performed each year world-wide and focuses on the associated radiation doses patients receive [1]. The research also found overall radiation exposure from
Whole-body SPECT/CT bone scan times to detect metastatic tumors in prostate cancer patients could be cut by half with the use of faster acquisition techniques, according to a study published December 12 in EJNMMI Physics.
POINT Biopharma Global Inc. (“POINT”) (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals
OncoBeta® GmbH today announced the Steve Biko Academic Hospital in Pretoria, South Africa, is participating in the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT – for the treatment of non-melanoma skin cancer).
Researchers at the Institute of Modern Physics (IMP) of the Chinese Academy of Sciences (CAS) have conducted a study on the separation route of germanium-68 and successfully prepared a germanium-68/gallium-68 generator.
Prostate-specific membrane antigen (PSMA) PET/CT imaging can reveal metastatic bone cancer lesions in prostate cancer patients that may be undetected by conventional bone scintigraphy, according to a group in the Netherlands.
Major new plans to make Wales a global centre of excellence and the leading location for medical radioisotope production in the UK,
NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging
A novel imaging agent, 68Ga-FAPI, can reduce the number of false-positive PET/CT findings among cancer patients recently vaccinated for COVID-19.
PET/CT imaging with an experimental F-18 prostate-specific membrane antigen (PSMA) radiotracer improves the care of patients with recurrent prostate cancer
Clinicians may now have a better idea of how best to treat men with intermediate- and high-risk and locally advanced prostate cancer.
POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery,
SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, will be supporting
A study in The Journal of Nuclear Medicine found 56.3% of Medicare patients with non-small cell lung cancer had FDG PET/CT imaging before radiation therapy
PET imaging with an experimental radiotracer called F-18 Florzolotau shows promise for the diagnosis of early progressive supranuclear palsy (PSP), a team of researchers has found.
Life Molecular Imaging (LMI) and Advanced Medical Support (AMS) announced today that both companies have entered into a strategic partnership and licensing agreement providing AMS with rights to have Florbetaben (18F) manufactured at the American Universi
The aim is to have production lines operating at the plant in Obninsk by 2025, supplying products for the diagnosis and treatment of patients, including a wide range of cancers. Rosatom says it will ensure Russia's sovereignty in the production of radioph
A PET/CT-based radiomics model appears promising for preselecting patients with non-small cell lung cancer (NSCLC) who may benefit from immunotherapy, according to a study published online January 22 in EJNMMI Research.
PET imaging with somatostatin receptor 2 (SST2) radiotracers shows major promise for diagnosis and therapeutic monitoring in patients with large-vessel vasculitis (LVV), according to a group in the U.K.
German doctors have reported finding a rare tenosynovial giant cell tumor (TGCT) in a COVID-19 patient's thigh using gallium-68 (Ga-68) fibroblast activation protein inhibitor (FAPI) PET imaging, according to a case published January 26 in the Journal of
